IMPACT BIOMEDICAL INC.
IMPACT BIOMEDICAL INC. (IBO): 9 pipeline candidates · 1 upcoming catalyst · ~1 mo cash runway · 5 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
0.8 months
D/E 0.21 · 0% dilution
Lead: Phase 2
9 candidates
1 upcoming, next in ~166d
0 buys · 3 sells (180d)
A transparent, data-derived signal for IMPACT BIOMEDICAL INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$62.2M
Cash
$20K
Quarterly Burn
$464K
Runway
0.8 mo
Revenue
$7K
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (9 candidates)
| Drug | Phase |
|---|---|
| energi-f705 | Phase 2 |
| equivir | Preclinical |
| hs-10374 | Phase 2 |
| impact computerized neurocognitive concussion management aid | — |
| linebacker | Preclinical |
| linebacker-1 | Preclinical |
| linebacker-2 | Preclinical |
| sgc001 | Phase 1 |
| zl-82 | Phase 1 |
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
18
Total value held
$2.6M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 1,416,336 | $850K |
| geode capital management, llc | 1,192,925 | $716K |
| state street corp | 607,897 | $365K |
| vanguard fiduciary trust co | 585,198 | $351K |
| blackrock, inc. | 259,946 | $156K |
| northern trust corp | 243,943 | $146K |
| two sigma investments, lp | 37,427 | $22K |
| morgan stanley | 9,274 | $6K |
| global trust asset management, llc | 1,818 | $1K |
| citigroup inc | 353 | $212 |
Showing top 10 of 18 institutional holders of IMPACT BIOMEDICAL INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in IMPACT BIOMEDICAL INC.'s pipeline?
IMPACT BIOMEDICAL INC. (IBO) has 9 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is IMPACT BIOMEDICAL INC.'s lead drug candidate?
IMPACT BIOMEDICAL INC.'s most advanced tracked candidate is energi-f705 (Phase 2) for Parkinson's Disease (PD).
What is IMPACT BIOMEDICAL INC.'s next catalyst?
IMPACT BIOMEDICAL INC.'s next tracked catalyst is a Phase2_Start event — "Phase 2 Start: A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Efficacy an" — expected December 1, 2026.
What is IMPACT BIOMEDICAL INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, IMPACT BIOMEDICAL INC. has approximately 0.8 months of cash runway.
What is IMPACT BIOMEDICAL INC.'s market capitalization?
IMPACT BIOMEDICAL INC.'s market capitalization is approximately $62.2M.
Get the full picture on IMPACT BIOMEDICAL INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.